Compare AQMS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | INTS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.2M |
| IPO Year | 2015 | 2021 |
| Metric | AQMS | INTS |
|---|---|---|
| Price | $5.49 | $5.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 47.1K | 27.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $600.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.19 |
| 52 Week High | $39.37 | $8.06 |
| Indicator | AQMS | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 71.73 | 41.61 |
| Support Level | $4.58 | $5.04 |
| Resistance Level | $8.37 | $8.06 |
| Average True Range (ATR) | 0.34 | 0.20 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 92.30 | 33.53 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.